PMC:7652766 / 26831-27070 JSONTXT

{"project":"LitCovid-PD-HP","denotations":[{"id":"T26","span":{"begin":101,"end":110},"obj":"Phenotype"},{"id":"T27","span":{"begin":143,"end":163},"obj":"Phenotype"},{"id":"T28","span":{"begin":188,"end":193},"obj":"Phenotype"}],"attributes":[{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0031273"}],"text":"Most COVID-19 patients exhibit mild to moderate symptoms, but approximately 15% progress to critical pneumonia and 5% eventually develop acute respiratory distress syndrome (ARDS), septic shock, multiple organ failure, and death (26, 108)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T137","span":{"begin":0,"end":239},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Most COVID-19 patients exhibit mild to moderate symptoms, but approximately 15% progress to critical pneumonia and 5% eventually develop acute respiratory distress syndrome (ARDS), septic shock, multiple organ failure, and death (26, 108)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1037","span":{"begin":89,"end":91},"obj":"Gene"},{"id":"1038","span":{"begin":36,"end":38},"obj":"Gene"},{"id":"1039","span":{"begin":14,"end":22},"obj":"Species"},{"id":"1040","span":{"begin":5,"end":13},"obj":"Disease"},{"id":"1041","span":{"begin":101,"end":110},"obj":"Disease"},{"id":"1042","span":{"begin":137,"end":172},"obj":"Disease"},{"id":"1043","span":{"begin":174,"end":178},"obj":"Disease"},{"id":"1044","span":{"begin":181,"end":193},"obj":"Disease"},{"id":"1045","span":{"begin":195,"end":217},"obj":"Disease"},{"id":"1046","span":{"begin":223,"end":228},"obj":"Disease"}],"attributes":[{"id":"A1037","pred":"tao:has_database_id","subj":"1037","obj":"Gene:6999"},{"id":"A1038","pred":"tao:has_database_id","subj":"1038","obj":"Gene:6999"},{"id":"A1039","pred":"tao:has_database_id","subj":"1039","obj":"Tax:9606"},{"id":"A1040","pred":"tao:has_database_id","subj":"1040","obj":"MESH:C000657245"},{"id":"A1041","pred":"tao:has_database_id","subj":"1041","obj":"MESH:D011014"},{"id":"A1042","pred":"tao:has_database_id","subj":"1042","obj":"MESH:D012128"},{"id":"A1043","pred":"tao:has_database_id","subj":"1043","obj":"MESH:D012128"},{"id":"A1044","pred":"tao:has_database_id","subj":"1044","obj":"MESH:D012772"},{"id":"A1045","pred":"tao:has_database_id","subj":"1045","obj":"MESH:D009102"},{"id":"A1046","pred":"tao:has_database_id","subj":"1046","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Most COVID-19 patients exhibit mild to moderate symptoms, but approximately 15% progress to critical pneumonia and 5% eventually develop acute respiratory distress syndrome (ARDS), septic shock, multiple organ failure, and death (26, 108)."}